Free Trial

Sanofi (SNY) Stock Forecast & Price Target

Sanofi logo
$46.97 +0.11 (+0.23%)
Closing price 09/17/2025 04:00 PM Eastern
Extended Trading
$47.28 +0.31 (+0.67%)
As of 09/17/2025 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sanofi - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
1
Buy
8

Based on 9 Wall Street analysts who have issued ratings for Sanofi in the last 12 months, the stock has a consensus rating of "Buy." Out of the 9 analysts, 1 has given a hold rating, 6 have given a buy rating, and 2 have given a strong buy rating for SNY.

Consensus Price Target

$62.67
33.42% Upside
According to the 9 analysts' twelve-month price targets for Sanofi, the average price target is $62.67. The highest price target for SNY is $65.00, while the lowest price target for SNY is $58.00. The average price target represents a forecasted upside of 33.42% from the current price of $46.97.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SNY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sanofi and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SNY Analyst Ratings Over Time

TypeCurrent Forecast
9/18/24 to 9/18/25
1 Month Ago
8/19/24 to 8/19/25
3 Months Ago
6/20/24 to 6/20/25
1 Year Ago
9/19/23 to 9/18/24
Strong Buy
2 Strong Buy rating(s)
3 Strong Buy rating(s)
3 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
6 Buy rating(s)
4 Buy rating(s)
3 Buy rating(s)
1 Buy rating(s)
Hold
1 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$62.67$62.00$61.50$57.50
Forecasted Upside33.42% Upside23.53% Upside28.50% Upside0.05% Upside
Consensus RatingBuyBuyBuyModerate Buy

SNY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SNY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Sanofi Stock vs. The Competition

TypeSanofiMedical CompaniesS&P 500
Consensus Rating Score
3.11
2.78
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside33.42% Upside18,066.39% Upside11.42% Upside
News Sentiment Rating
Positive News

See Recent SNY News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
9/8/2025Morgan Stanley
3 of 5 stars
Mark Purcell
Not Rated
UpgradeEqual WeightOverweight$56.00 ➝ $58.00+24.73%
9/2/2025Deutsche Bank Aktiengesellschaft
3 of 5 stars
UpgradeHoldBuy
8/8/2025JPMorgan Chase & Co.
2 of 5 stars
Richard Vosser
Not Rated
UpgradeNeutralOverweight
7/2/2025Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingOverweight
6/3/2025Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Reiterated RatingBuy
4/28/2025Hsbc Global Res
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
4/15/2025BNP Paribas
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$65.00+27.28%
3/21/2025The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageNeutral$65.00+12.48%
1/30/2025Sanford C. Bernstein
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
9/17/2024Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong-Buy
7/26/2024Argus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetBuy$55.00 ➝ $60.00+13.92%
10/30/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:05 AM ET.


Should I Buy Sanofi Stock? SNY Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Wednesday, September 17, 2025. Please send any questions or comments about these Sanofi pros and cons to contact@marketbeat.com.

Sanofi
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Sanofi:

  • The current stock price is around $48.81, which is relatively stable compared to its 52-week high of $60.12, indicating potential for growth.
  • Sanofi reported a strong revenue of $11.34 billion in its latest quarterly earnings, exceeding analyst expectations, which reflects robust business performance.
  • The company has a solid net margin of 21.47%, suggesting effective cost management and profitability, which can lead to higher returns for investors.
  • With a low debt-to-equity ratio of 0.19, Sanofi demonstrates financial stability, indicating that it is less reliant on debt for financing, which can reduce risk for investors.
  • The company has a return on equity of 16.86%, showcasing its ability to generate profits from shareholders' equity, which is a positive sign for potential investors.

Sanofi
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Sanofi for these reasons:

  • Sanofi's earnings per share (EPS) of $0.90 missed analysts' consensus estimates, indicating potential challenges in meeting market expectations.
  • The company's revenue has decreased by 7.0% compared to the same quarter last year, which may raise concerns about its growth trajectory.
  • With a price-to-earnings (P/E) ratio of around 11.10, while it may seem attractive, it could also suggest that the stock is not significantly undervalued compared to its peers.
  • The stock has a beta of 0.51, indicating lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • Sanofi's quick ratio of 0.94 is below 1, suggesting that the company may face challenges in meeting its short-term liabilities, which could be a red flag for investors.

SNY Forecast - Frequently Asked Questions

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Sanofi is $62.67, with a high forecast of $65.00 and a low forecast of $58.00.

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last twelve months. There is currently 1 hold rating, 6 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNY shares.

According to analysts, Sanofi's stock has a predicted upside of 33.42% based on their 12-month stock forecasts.

Over the previous 90 days, Sanofi's stock had 3 upgrades by analysts.

Sanofi has been rated by research analysts at Barclays, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., and Morgan Stanley in the past 90 days.

Analysts like Sanofi more than other "medical" companies. The consensus rating for Sanofi is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how SNY compares to other companies.


This page (NASDAQ:SNY) was last updated on 9/18/2025 by MarketBeat.com Staff
From Our Partners